Trinseo (NYSE: TSE), a global materials solutions provider and manufacturer of plastics, latex binders and synthetic rubber, will introduce its portfolio of thermoplastic elastomers (TPEs) for medical devices at two major industry shows: MD&M West in Anaheim, Calif. from February 5-7 at Booth 1986 and Pharmapack EU in Paris from February 6-7 at Booth D94. This portfolio of TPEs complements Trinseo’s traditional rigid plastics offering, making Trinseo a one-stop-shop for both hard and soft plastics.
Trinseo has supported the medical devices market for nearly three decades and is known for superior product quality, outstanding consistency, and a focus on customer compliancy requirements. The expanded portfolio enhances Trinseo’s offering with soft touch materials and overlays that are often needed with hard plastics.
TPEs can serve as a vinyl substitute. With their elastomeric composition, TPEs can allow better handling of medical devices and potentially increase performance, functionality, usability, and aesthetics, while helping to improve patient care and contribute to patient safety.
“We've brought together a very high quality portfolio of rigid plastics with TPEs that have been specifically formulated for the medical devices sector,” said Aldo Zanetti, business unit manager TPE Solutions - Medical & Packaging for Trinseo. “This move helps us meet the needs of medical customers, particularly as the industry addresses trends in health care that require medical devices and equipment that are more patient friendly and service provider friendly.”
Trinseo offers two styrenic block copolymers (TPSs) to the medical devices industry under the brands MEGOL™ and RAPLAN™. Materials are biocompatibility tested and available with full biocompatibility (MED) and limited testing approved for skin contact (SK), providing customers with the most economical material option, since not all medical devices require full biocompatibility.
Trinseo’s rigid plastics for medical devices include:
Trinseo supports medical devices customers with material solutions for Single and Multiple Use Devices, Equipment Housings, Drug Delivery Systems, and Medical Wearables. As the medical industry continues to evolve and bring life-enhancing devices to market, global medical device and pharmaceutical manufacturers rely on Trinseo to respond with materials developed to meet their needs. The company adheres to current Good Manufacturing Practices (cGMP) and holds an ISO 13485 certification.
Trinseo (NYSE:TSE) is a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber with a focus on delivering innovative, sustainable, and value-creating products that are intrinsic to our daily lives. Trinseo is dedicated to making a positive impact on society by partnering with like-minded stakeholders, and supporting the sustainability goals of our customers in a wide range of end-markets including automotive, consumer electronics, appliances, medical devices, packaging, footwear, carpet, paper and board, building and construction, and tires. Trinseo had approximately $3.8 billion in net sales with 2,700 employees globally in 2019. For more information, please visit: www.trinseo.com.
This press release may contain “forward-looking statements” including, without limitation, statements concerning plans, objectives, goals, projections, expectations, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts. Forward-looking statements may be identified by the use of words like “expect,” “estimate,” “will,” “may,” or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on the Company’s current expectations and assumptions regarding the impact from the COVID-19 pandemic, the Company’s business, the economy and other future conditions. Specific factors that could cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, risks related to the ongoing impact of the COVID-19 pandemic and those discussed in the Company’s Annual Report for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”), in subsequent Quarterly Reports on Form 10-Q and in other filings and furnishings made by the Company with the SEC from time to time. Other unknown or unpredictable factors could also have material adverse effects on the Company’s performance. As a result of these or other factors, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof and are not a guarantee of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.